FY2025 · ended Dec 31, 2025 · Revenue $7.14M, -72.5% YoY · Filed Mar 12, 2026
Whitehawk Therapeutics, Inc. (WHWK) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $7.1 million and a net loss of $20.6 million. Free cash flow was -$98.0 million.
Revenue (TTM)
$0
-100.0% vs year-ago TTM
Net income (TTM)
$-79.83M
-666.3% vs year-ago TTM
Operating cash flow (TTM)
$-69.35M
+27.4% vs year-ago TTM
Free cash flow (TTM)
$-69.35M
+28.1% vs year-ago TTM
EPS (TTM)
$-1.10
-332.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
47.20M
+0.9% vs prior year
Net cash
$145.70M
FY 2025
Operating margin
-1601.1%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- WHWK (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Morristown, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1422142
- Former names
- Aadi Bioscience, Inc. (until Mar 18, 2025); Aerpio Pharmaceuticals, Inc. (until Aug 23, 2021); ZETA ACQUISITION CORP II (until Mar 13, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.1M | $26.0M | $24.4M | $15.2M | $14.0M |
| Operating income | -$114.4M | -$67.5M | -$71.9M | -$62.7M | -$111.2M |
| Net income | -$20.6M | -$63.7M | -$65.8M | -$60.5M | -$110.1M |
| Diluted EPS | -$0.33 | -$2.36 | -$2.44 | -$2.69 | — |
| Operating cash flow | -$97.4M | -$59.5M | -$59.7M | -$49.6M | -$22.4M |
| Free cash flow | -$98.0M | -$61.2M | -$63.6M | -$50.1M | -$22.5M |
| Total assets | $150.8M | $70.3M | $132.4M | $184.2M | $157.9M |
| Total liabilities | $14.5M | $17.8M | $27.2M | $25.9M | $21.5M |
| Stockholders' equity | $136.3M | $52.5M | $105.2M | $158.4M | $136.4M |
| Cash and investments | $145.7M | $47.2M | $108.8M | $172.6M | $149.0M |
| Total debt | $0 | $833,000 | $1.3M | $1.7M | $605,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 10, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Other events
|
May 21, 2026 | May 21, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
May 13, 2026 | May 12, 2026 |
All 671 Whitehawk Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.